Business Wire | Dec 10, 2020 01:03PM EST

Company Profile for AlloVir

Dec. 10, 2020

--(BUSINESS WIRE)--Dec. 10, 2020--AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company's innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

Company: AlloVir



Headquarters Address: 139 Main Street

Suite 500

Cambridge, MA 02142



Main Telephone: 617-433-2605



Website: www.allovir.com



Ticker/ISIN: ALVR(NASDAQ)/US0198181036



Type of Organization: Public



Industry: Biotechnology



Key Executives: CEO: David Hallal

CFO: Vikas Sinha



Investor Relations

Contact: Medha Chadha

Phone: 917-765-2125

Email: Mchadha@allovir.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005944/en/